Angoulvant, Denis

Efficacy and safety of low-dose colchicine after myocardial infarction

Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine

Acute Myocardial Infarction ResearchCardiac Fibrosis and Remodeling

Cited by 3,159

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

Cung, T.-T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., Bonnefoy-Cudraz, E., Guérin, P., Elbaz, M., Delarche, N., et al. (2015) · New England Journal of Medicine

Cardiac Ischemia and ReperfusionAcute Myocardial Infarction Research

Cited by 713

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 209

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 72

Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project

Philippart, R., Brunet-Bernard, A., Clementy, N., Bourguignon, T., Mirza, A., Babuty, D., Angoulvant, D., Lip, G. Y. H., & Fauchier, L. (2015) · European Heart Journal

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 68

Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis

Bisson, A., Bodin, A., Fauchier, G., Herbert, J., Angoulvant, D., Ducluzeau, P. H., Lip, G. Y. H., & Fauchier, L. (2021) · Cardiovascular Diabetology

Atrial Fibrillation Management and OutcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 44

Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes

Angoulvant, D., Peyronnet, E., Cariou, B., Amarenco, P., Boccara, F., Boissel, J.-P., Bastien, A., Courcelles, E., Diatchenko, A., Filipovics, A., et al. (2026) · European Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 4